Tenaya Therapeutics, Inc. (TNYA) 10-Year Financial Performance & Capital Metrics

TNYA • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutTenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.Show more

Revenue $0
EBITDA -$107M +12.3%
Net Income -$111M +10.4%
EPS (Diluted) -1.31 +22.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -95.69% -47.6%
ROIC -83.49% -14.3%
Debt/Equity 0.15 +64.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.7x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 15.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM19.59%

EPS CAGR

10Y-

5Y-

3Y-

TTM47.3%

ROCE

10Y Avg-60.34%

5Y Avg-56.05%

3Y Avg-67.67%

Latest-92.11%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	1.99M	2.48M	4.03M	8.71M	8.69M	8.47M
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	-1.99M	-2.48M	-4.03M	-8.71M	-8.69M	-8.47M
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-0.25%	-0.62%	-1.16%	0%	0.03%
Operating Expenses+	27.71M	36.43M	68.78M	116.91M	122.51M	107.48M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	4.56M	5.33M	14.39M	22.37M	24.47M	20.74M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	23.15M	31.1M	54.39M	94.54M	98.04M	86.74M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	1.03M	0	0	0	0	0
Operating Income+	-27.71M	-38.91M	-72.81M	-125.62M	-131.19M	-115.95M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	-0.4%	-0.87%	-0.73%	-0.04%	0.12%
EBITDA+	-25.72M	-36.43M	-68.78M	-116.91M	-122.51M	-107.48M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-0.42%	-0.89%	-0.7%	-0.05%	0.12%
D&A (Non-Cash Add-back)	1.99M	2.48M	4.03M	8.71M	8.69M	8.47M
EBIT	-27.71M	-38.4M	-72.72M	-123.67M	-124.08M	-111.13M
Net Interest Income+	453K	87K	108K	1.95M	7.06M	4.74M
Interest Income	453K	87K	108K	1.95M	7.06M	4.74M
Interest Expense	0	0	0	0	0	0
Other Income/Expense	1.48M	517K	85K	1.96M	7.11M	4.82M
Pretax Income+	-26.23M	-38.4M	-72.72M	-123.67M	-124.08M	-111.13M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	0.98%	1%	1%	1%	1%	1%
Net Income+	-25.78M	-38.4M	-72.72M	-123.67M	-124.08M	-111.13M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-0.49%	-0.89%	-0.7%	-0%	0.1%
Net Income (Continuing)	-26.23M	-38.4M	-72.72M	-123.67M	-124.08M	-111.13M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.95	-0.93	-1.69	-2.76	-1.68	-1.31
EPS Growth %	-	0.02%	-0.82%	-0.63%	0.39%	0.22%
EPS (Basic)	-0.95	-0.93	-1.69	-2.76	-1.68	-1.31
Diluted Shares Outstanding	27.2M	41.12M	41.29M	44.82M	73.79M	84.82M
Basic Shares Outstanding	27.2M	41.12M	41.29M	44.82M	73.79M	84.82M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	27.74M	129.96M	255.36M	193.75M	111.58M	67.38M
Cash & Short-Term Investments	26.63M	128.53M	251.3M	186.53M	104.64M	61.45M
Cash Only	23.87M	128.53M	38.13M	95.27M	45.68M	4.32M
Short-Term Investments	2.75M	0	213.17M	91.25M	58.96M	57.12M
Accounts Receivable	0	0	0	2.25M	0	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	4.06M	938K	1.16M	842K
Total Non-Current Assets+	10.26M	18.2M	61.29M	85.19M	58.93M	52.56M
Property, Plant & Equipment	9.57M	17.18M	54.7M	62.7M	53.26M	47.75M
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	485K	0	547K	17.7M	0	0
Other Non-Current Assets	199K	1.01M	3.58M	4.79M	5.68M	4.82M
Total Assets+	38M	148.16M	316.65M	278.94M	170.51M	119.94M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	2.9%	1.14%	-0.12%	-0.39%	-0.3%
Total Current Liabilities+	4.12M	5.04M	21.77M	24.25M	22.73M	15.97M
Accounts Payable	600K	1.02M	10.72M	9.58M	5.63M	5.16M
Days Payables Outstanding	110.11	149.5	972.21	401.24	236.55	222.5
Short-Term Debt	0	0	1.99M	0	0	2.78M
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	1.94M	1.22M	5.39M	6.97M	9.27M	5.81M
Current Ratio	6.73x	25.78x	11.73x	7.99x	4.91x	4.22x
Quick Ratio	6.73x	25.78x	11.73x	7.99x	4.91x	4.22x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	77.62M	3.68M	16.35M	11.32M	8.36M	11.11M
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	0	13.71M	11.09M	8.11M	10.83M
Deferred Tax Liabilities	0	0	2.46M	0	0	0
Other Non-Current Liabilities	77.62M	3.68M	182K	228K	253K	281K
Total Liabilities	81.74M	8.72M	38.12M	35.57M	31.09M	27.09M
Total Debt+	0	0	15.7M	15.1M	12.42M	13.61M
Net Debt	-23.87M	-128.53M	-22.43M	-80.17M	-33.26M	9.29M
Debt / Equity	-	-	0.06x	0.06x	0.09x	0.15x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-
Total Equity+	-43.74M	139.44M	278.53M	243.38M	139.42M	92.85M
Equity Growth %	-	4.19%	1%	-0.13%	-0.43%	-0.33%
Book Value per Share	-1.61	3.39	6.75	5.43	1.89	1.09
Total Shareholders' Equity	-43.74M	139.44M	278.53M	243.38M	139.42M	92.85M
Common Stock	1K	0	4K	7K	7K	8K
Retained Earnings	-44.42M	-82.81M	-155.53M	-279.2M	-403.28M	-514.41M
Treasury Stock	12.96K	0	0	0	0	0
Accumulated OCI	-74.04K	-87K	-141K	-378K	-106K	28K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-24.1M	-35.45M	-60.81M	-104.42M	-102.07M	-90.5M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-0.47%	-0.72%	-0.72%	0.02%	0.11%
Net Income	-26.23M	-38.4M	-72.72M	-123.67M	-124.08M	-111.13M
Depreciation & Amortization	1.99M	2.48M	2.96M	6.47M	8.69M	8.47M
Stock-Based Compensation	414K	741K	2.95M	11.47M	15.31M	16.5M
Deferred Taxes	-82K	0	0	0	0	0
Other Non-Cash Items	64K	-42K	1.26M	2.16M	3.66M	3.59M
Working Capital Changes	-250K	-234K	4.74M	-849K	-5.65M	-7.93M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	397K	142K	8.6M	1.66M	-3.28M	-581K
Cash from Investing+	-5.58M	-7.01M	-238.56M	83.65M	48.72M	1.13M
Capital Expenditures	-2.93M	-9.76M	-25.12M	-20.63M	-1.24M	-1.02M
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	-2.66K	0	0	8K	-25K	17K
Cash from Financing+	30.51M	147.27M	208.97M	77.77M	4.05M	47.75M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	68K	34K	461K	380K	181K	987K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-27.02M	-45.21M	-85.93M	-125.05M	-103.31M	-91.53M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-0.67%	-0.9%	-0.46%	0.17%	0.11%
FCF per Share	-0.99	-1.10	-2.08	-2.79	-1.40	-1.08
FCF Conversion (FCF/Net Income)	0.93x	0.92x	0.84x	0.84x	0.82x	0.81x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-80.24%	-34.8%	-47.39%	-64.83%	-95.69%
Return on Invested Capital (ROIC)	-	-	-40.9%	-44.94%	-73.06%	-83.49%
Debt / Equity	-	-	0.06x	0.06x	0.09x	0.15x
FCF Conversion	0.93x	0.92x	0.84x	0.84x	0.82x	0.81x

Frequently Asked Questions

Growth & Financials

Tenaya Therapeutics, Inc. (TNYA) grew revenue by 0.0% over the past year. Growth has been modest.

Tenaya Therapeutics, Inc. (TNYA) reported a net loss of $94.3M for fiscal year 2024.

Dividend & Returns

Tenaya Therapeutics, Inc. (TNYA) has a return on equity (ROE) of -95.7%. Negative ROE indicates the company is unprofitable.

Tenaya Therapeutics, Inc. (TNYA) had negative free cash flow of $73.5M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener